A multicenter ascending dose, double blind, placebo-controlled study of NAP (AL-108) in chronic schizophrenia.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Davunetide (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Apr 2012 Actual patients number is 63 as reported by ClinicalTrials.gov.
- 12 Aug 2011 Magnetic Resonance Imaging data from 23 patients in this study was reported in an Allon media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History